Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
COVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, stu...
| Autor: | |
|---|---|
| Tipo de documento: | dissertação |
| Estado: | Versão publicada |
| Data de publicação: | 2023 |
| País: | Brasil |
| Recursos: | Universidade Federal de Minas Gerais (UFMG) |
| Repositório: | Repositório Institucional da UFMG |
| Idioma: | português |
| OAI Identifier: | oai:repositorio.ufmg.br:1843/55418 |
| Acesso em linha: | http://hdl.handle.net/1843/55418 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Microbiologia COVID-19 Bromelaínas Acetilcisteína Covid-19 |
| Resumo: | COVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, studies focusing on compounds controlled intranasally to act more quickly in the airways and mucous membranes of individuals with severe COVID-19 under mechanical ventilation are still reduced. In this sense, BromAc® is a combination of bromelain and acetylcysteine (NAC), currently used for the treatment of pseudomyxoma (Phase 3) and has been studied for repositioning in the treatment of COVID-19. Therefore, in the present study, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® ex-vivo in a sample of tracheal aspirates from critically ill patients with COVID-19 under mechanical ventilation and the anti-inflammatory effect of BromAc® in an in vitro system using peripheral blood cells stimulated with inactivated SARS-CoV-2. Our results sadden that BromAc® exhibited a robust mucolytic effect in the exception of tracheal aspirates from patients with COVID-19 in a dose-dependent manner. In addition, BromAc® has demonstrated anti-inflammatory activity, reducing the cytokine storm in the tracheal aspirate samples from patients with COVID-19 and in culture supernatants. The combination showed reduced chemokines compared to NAC individually. The action of the combined compounds on regulatory cytokines such as IL-10 was also observed. Furthermore, BromAc® was able to modulate CD16+ and CD14+ cells after in vitro treatment of blood cells with BromAc®. These results indicate a robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill patients, indicating its potential as a therapeutic strategy for COVID-19. Clinical trials are needed to define the safety and efficacy of BromAc® in the treatment of the disease, which has been the greatest challenge of the 21st century. |
|---|